Infectious Disease
Circa 400 BCE, Ancient Greece — epidemic jaundice descriptions in Hippocratic corpus, though hepatitis C as a distinct entity was first documented as non-A, non-B hepatitis in 1974–1975 by Harvey Alter and colleagues
Hepatitis C was one of the most consequential infectious disease discoveries of the late twentieth century, identified only after decades in which a mysterious form of post-transfusion liver illness confounded physicians who had already isolated hepatitis A and hepatitis B. The condition existed as a clinical puzzle under the provisional label non-A, non-B hepatitis for over a decade before molecular biological techniques finally revealed the causative virus in 1989. Its history was inseparable from the evolution of blood banking, virology, and the molecular tools that transformed infectious disease research.
Historical Narrative
Liver disease attributed to infectious causes had been observed and debated for centuries before the distinct viral agents responsible were identified. Ancient Greek and Roman physicians recognized jaundice as a clinical phenomenon and speculated about contagious forms of liver illness. Medieval European physicians described epidemic jaundice outbreaks and attributed them variously to corrupted air, humoral imbalance, or divine affliction. These early accounts lacked any means of distinguishing among the multiple distinct conditions that could produce jaundice, and the concept of a specific viral agent was entirely foreign to pre-germ theory medicine.
The modern understanding of infectious hepatitis began to take shape during the late nineteenth and early twentieth centuries as germ theory became the dominant explanatory framework. Military physicians during World War I and especially World War II observed large outbreaks of jaundice among troops that appeared to spread through both contaminated water and through injections, suggesting at least two distinct transmission routes. These wartime observations were foundational in establishing that infectious jaundice encompassed more than one disease entity.
After World War II, careful clinical and epidemiological research by Findlay, MacCallum, and others in Britain helped establish the distinction between infectious hepatitis, transmitted by the oral-fecal route, and serum hepatitis, transmitted through blood. MacCallum proposed the terminology hepatitis A and hepatitis B in 1947, though the actual viral agents behind these designations remained uncharacterized for years. This two-category framework dominated hepatology through the 1950s and into the 1960s.
The discovery of the Australia antigen by Baruch Blumberg in 1965 provided the first serological marker for what would be confirmed as hepatitis B virus. Blumberg, working at the National Institutes of Health and later the Institute for Cancer Research, had been studying inherited variations in blood proteins when he identified a novel antigen in the serum of an Australian Aboriginal person. Subsequent work by Alfred Prince and others linked this antigen to serum hepatitis, and a blood test for hepatitis B became available by the early 1970s. Blood banks began screening donations, and transfusion-associated hepatitis B declined significantly.
However, post-transfusion hepatitis did not disappear after hepatitis B screening was introduced. A substantial proportion of patients who received blood transfusions still developed hepatitis that could not be attributed to either hepatitis A or hepatitis B. Harvey Alter at the National Institutes of Health led systematic research documenting this residual post-transfusion hepatitis through the 1970s, establishing through careful chimpanzee transmission experiments that it was caused by an unidentified infectious agent. This entity was designated non-A, non-B hepatitis, a frustrating placeholder that acknowledged ignorance of the causative organism.
The virus remained elusive throughout the 1980s because it was present in infected blood in quantities too small to detect by conventional virological methods and resisted growth in standard cell cultures. The breakthrough came in 1989 when Michael Houghton and colleagues at Chiron Corporation, collaborating with Alter's group, used a novel molecular cloning approach to identify the viral genome from infected chimpanzee plasma. The virus was named hepatitis C, and a diagnostic blood test was developed rapidly thereafter. Blood banks worldwide implemented screening, and transfusion-associated hepatitis C was dramatically curtailed within a few years of the test's introduction.
Key Historical Figures
Historical narrative only — this page describes how Hepatitis C was understood historically. It is not medical advice and does not describe current diagnosis or treatment. Sourced from verified medical history references (NIH, Encyclopaedia Britannica, and standard medical history texts). See our medical disclaimer.